NEW YORK (GenomeWeb News) — Zebrafish-screening firm Znomics said today that it is collaborating with Oregon Health & Science University to develop pre-clinical compounds to treat diseases such as rheumatoid arthritis, asthma, and inflammatory bowel syndrome.
The company said it will be collaborating with Thomas Scanlan, director of OHSU’s chemical biology program, on the project. Scanlan has been a member of Znomics' scientific advisory board since December 2007.
Under the terms of the agreement, Znomics will fund the program and will have the option to exclusively license the rights to the discoveries.
The company said that the collaboration meets its objective of establishing three de novo drug discovery programs this year, and that it plans to have three pre-clinical lead compounds in different disease areas in 2010.
In addition to the disease areas covered in the OHSU collaboration, the firm has a drug discovery program in obesity and a collaborative drug discovery program with the University of Utah that it signed earlier this year to develop compounds for the treatment of T-cell diseases, including leukemia, lymphoma, and autoimmune disorders.